Inclusion Criteria:

- 18 years of age and older

- Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer,
primary peritoneal carcinoma, or papillary serous mullerian carcinoma

- Previous attempted surgical debulking

- Stage III or IV

- Willing and able to undergo second look laparoscopy

- Performance status 0-1 by ECOG scale

- Peripheral neuropathy < grade 2

- Life expectancy of 6 months or greater

Exclusion Criteria:

- Patients with clinically significant cardiovascular disease as outlined in the
protocol

- Neutrophil count < 1,500/mm3; platelet count <100,000/m3

- Alkaline phosphatase or bilirubin > 1.5 x ULN, SGOT > 5 x ULN

- Calculated creatinine clearance < 50ml/min

- Prior chemotherapy or radiotherapy for other malignancy except for the treatment for
localized breast cancer greater than five years prior to diagnosis

- No more than one cycle of first line chemotherapy with carboplatin and paclitaxel

- Inadequate surgical cytoreduction such that interval cytoreductive surgery could
materially improve prognosis

- Concurrent invasive malignancy

- Evidence of bleeding diathesis or coagulopathy

- Evidence of tumor involving major blood vessels on any prior CT scans

- Surgical wound that has failed to close

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 0, or anticipation of need for major surgical procedure during the
course of this study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to day 0

- Serious non-healing wound, ulcer, or bone fracture

- Prior treatment with an anti-angiogenic agent

- Any active bleeding

- Active psychiatric disease or neurologic symptoms requiring treatment

- Presence of central nervous system brain metastases

- Proteinuria at screening as demonstrated by criteria in protocol

- Dementia or significantly altered mental status that would prohibit the understanding
and/or giving of informed consent

- Known hypersensitivity to Cremophor EL or any component of Avastin

- Active bacterial, viral, or fungal infections

- Receiving any other investigational agent

- History of gastrointestinal perforation

- Prior therapies targeting the epidermal growth factor receptor

- Symptoms of bowel obstruction

- Dependence on TPN or IV hydration